Frankfurt - Delayed Quote EUR

GH Research PLC (1KA.F)

10.70
-0.90
(-7.76%)
At close: June 13 at 9:15:05 AM GMT+2
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
0
0
Operating Expense
51,519
50,246
41,221
30,675
15,100
Operating Income
-51,519
-50,246
-41,221
-30,675
-15,100
Net Non Operating Interest Income Expense
5,960
5,558
5,305
735
-9
Other Income Expense
3,452
5,727
329
7,484
5,907
Pretax Income
-42,107
-38,961
-35,587
-22,456
-9,202
Tax Provision
0
0
0
0
0
Net Income Common Stockholders
-42,107
-38,961
-35,587
-22,456
-9,202
Diluted NI Available to Com Stockholders
-42,107
-38,961
-35,587
-22,456
-9,202
Basic EPS
-0.79
--
-0.68
-0.43
-0.21
Diluted EPS
-0.79
--
-0.68
-0.43
-0.21
Basic Average Shares
53,528.15
--
52,333.82
52,020.85
43,683.30
Diluted Average Shares
53,528.15
--
52,333.82
52,020.85
43,683.30
Total Operating Income as Reported
-51,516
-50,312
-41,222
-30,554
-15,100
Total Expenses
51,519
50,246
41,221
30,675
15,100
Net Income from Continuing & Discontinued Operation
-42,107
-38,961
-35,587
-22,456
-9,202
Normalized Income
-45,559
-44,688
-35,916
-29,940
-15,109
Interest Income
6,676
6,275
6,028
858
0
Interest Expense
45
48
63
0
9
Net Interest Income
5,960
5,558
5,305
735
-9
EBIT
-42,062
-38,913
-35,524
-22,456
-9,193
EBITDA
-41,751
-38,598
-35,209
-22,409
-9,174
Reconciled Depreciation
311
315
315
47
19
Net Income from Continuing Operation Net Minority Interest
-42,107
-38,961
-35,587
-22,456
-9,202
Total Unusual Items Excluding Goodwill
3,452
5,727
329
7,484
5,907
Total Unusual Items
3,452
5,727
329
7,484
5,907
Normalized EBITDA
-45,203
-44,325
-35,538
-29,893
-15,081
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 7/26/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

9VC.MU ATAI Life Sciences NV
1.9300
-2.18%
 
9VC.DE Atai Life Sciences N.V.
1.8545
-2.83%
 
9VC.F Atai Life Sciences N.V.
1.7920
-1.86%
 
NEUP Neuphoria Therapeutics Inc.
6.82
-5.40%
 
AKRO Akero Therapeutics, Inc.
55.62
+3.85%
 
CYBN Cybin Inc.
8.35
-3.47%
 
ATAI Atai Life Sciences N.V.
2.1100
-3.21%
 
EYEN Eyenovia, Inc.
2.4400
-8.61%